Associated Papers
Association of methylenetetrahydrofolate reductase (MTHFR) C677T, MTHFR A1298C, and CYP3A4 A290G gene polymorphisms with clinical outcomes of HLA-matched sibling allogeneic hematopoietic cell transplantation in an Egyptian patient/donor cohort.
ElFishawi S et al.
Human Immunology, 2025
A descriptive study of the single-nucleotide polymorphisms known to affect the Tacrolimus trough concentration per dose, among a population of kidney failure patients in a tertiary hospital in Ghana.
Kwakyi E et al.
Bmc Research Notes, 2024
When the same treatment has different response: The role of pharmacogenomics in statin therapy.
Zheng E et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2024
Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?
Maslub MG et al.
European Journal of Medical Research, 2023
Importance of Pharmacogenetics and Drug-Drug Interactions in a Kidney Transplanted Patient.
Concha J et al.
Life (basel, Switzerland), 2023
Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts.
Dagli-Hernandez C et al.
Pharmacological Reports : Pr, 2022
Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia.
Hindi NN et al.
Journal of Personalized Medicine, 2021
A review of the existing literature on buprenorphine pharmacogenomics.
Meaden CW et al.
The Pharmacogenomics Journal, 2021
Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine.
Abijo T et al.
Current Neuropharmacology, 2020
Pharmacogenetics of statins treatment: Efficacy and safety.
Guan ZW et al.
Journal of Clinical Pharmacy and Therapeutics, 2019
Germline polymorphisms and the risk of therapy-related myeloid neoplasms.
Takahashi K
Best Practice & Research. Clinical Haematology, 2019
The Influence of CYP3A4 Polymorphism in Sex Steroids as a Risk Factor for Breast Cancer.
Veiga MG et al.
Revista Brasileira De Ginecologia E Obstetricia : Revista Da Federacao Brasileira Das Sociedades De Ginecologia E Obstetricia, 2018
Influence of UGT2B7, CYP3A4, and OPRM1 Gene Polymorphisms on Transdermal Buprenorphine Pain Control in Patients with Critical Lower Limb Ischemia Awaiting Revascularization.
Blanco F et al.
Pain Practice : the Official Journal of World Institute of Pain, 2016
Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors.
Deshpande N et al.
Meta Gene, 2016
135G/C polymorphism in the RAD51 gene and acute myeloid leukemia risk: a meta-analysis.
Wu L et al.
Genetics and Molecular Research : Gmr, 2016
SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
Prado Y et al.
International Journal of Molecular Sciences, 2015
CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin.
Kolovou G et al.
Genetics and Molecular Biology, 2015
Prognostic Value of a CYP2B6 Gene Polymorphism in Patients with Acute Myeloid Leukemia.
Alazhary NM et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2015
Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients.
Kuypers DR et al.
Pharmacogenetics and Genomics, 2014
The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes.
Fabiani E et al.
Leukemia & Lymphoma, 2014
The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients.
Schoeppler KE et al.
Clinical Transplantation, 2014
The PXR rs7643645 polymorphism is associated with the risk of higher prostate-specific antigen levels in prostate cancer patients.
Reyes-Hernández OD et al.
Plos One, 2014
Pharmacogenetics in perioperative medicine.
Cohen M et al.
Current Opinion in Anaesthesiology, 2012
Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.
Rosales A et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2012
Evaluating the effect of 3 glucocorticoid receptor gene polymorphisms on risk of relapse in 100 Iranian children with acute lymphoblastic leukemia: a case-control study.
Namazi S et al.
Clinical Therapeutics, 2011
Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?
Magliulo L et al.
European Journal of Clinical Pharmacology, 2011
Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
Harmsze A et al.
Pharmacogenetics and Genomics, 2010
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes.
Fabiani E et al.
Leukemia Research, 2009
Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India.
Singh R et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2009
Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes?
Singh V et al.
Cancer Investigation, 2008
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes.
Voso MT et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2007
The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia.
Bolufer P et al.
Haematologica, 2007
Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma.
Schilthuizen C et al.
Haematologica, 2007
Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia.
Bolufer P et al.
British Journal of Haematology, 2007
Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression.
Bolufer P et al.
Leukemia Research, 2006
Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.
Kim KA et al.
Clinical Pharmacology and Therapeutics, 2006
[Association between polymorphisms of CYP17 and CYP3A4 genes and intrahepatic cholestasis of pregnancy in Chengdu].
Zhang L et al.
Sichuan Da Xue Xue Bao. Yi Xue Ban = Journal of Sichuan University. Medical Science Edition, 2006
Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.
van Schaik RH
Investigational New Drugs, 2005
Genetic polymorphisms of cytochrome P450 among patients with Balkan endemic nephropathy (BEN).
Atanasova SY et al.
Clinical Biochemistry, 2005
CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia.
Kajinami K et al.
The American Journal of Cardiology, 2004
Polymorphisms in genes involved in the corticosteroid response and the outcome of childhood acute lymphoblastic leukemia.
Fleury I et al.
American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice, 2004
Genetic basis of drug metabolism.
Ma MK et al.
American Journal of Health-system Pharmacy : Ajhp : Official Journal of the American Society of Health-system Pharmacists, 2002
Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.
Dai D et al.
The Journal of Pharmacology and Experimental Therapeutics, 2001
Pharmacogenomics of buprenorphine - a narrative review.
Aravindan L et al.
Pharmacogenomics, 0